Boston Scientific Statistics
Share Statistics
Boston Scientific has 1.48B
shares outstanding. The number of shares has increased by 0.6%
in one year.
| Shares Outstanding | 1.48B |
| Shares Change (YoY) | 0.6% |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | 90.6% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 69 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 15.71M, so 1.06% of the outstanding
shares have been sold short.
| Short Interest | 15.71M |
| Short % of Shares Out | 1.06% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 1.95 |
Valuation Ratios
The PE ratio is 70.89 and the forward
PE ratio is 31.62.
Boston Scientific's PEG ratio is
4.25.
| PE Ratio | 70.89 |
| Forward PE | 31.62 |
| PS Ratio | 7.85 |
| Forward PS | 5.6 |
| PB Ratio | 6.04 |
| P/FCF Ratio | 49.69 |
| PEG Ratio | 4.25 |
Financial Ratio HistoryEnterprise Valuation
Boston Scientific has an Enterprise Value (EV) of 142.17B.
| EV / Sales | 8.49 |
| EV / EBITDA | 36.08 |
| EV / EBIT | 41.39 |
| EV / FCF | 53.75 |
Financial Position
The company has a current ratio of 1.08,
with a Debt / Equity ratio of 0.51.
| Current Ratio | 1.08 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 2.83 |
| Debt / FCF | 4.21 |
| Interest Coverage | 8.53 |
Financial Efficiency
Return on Equity is 8.52% and Return on Invested Capital is 6.06%.
| Return on Equity | 8.52% |
| Return on Assets | 4.71% |
| Return on Invested Capital | 6.06% |
| Revenue Per Employee | $315,981.13 |
| Profits Per Employee | $34,981.13 |
| Employee Count | 53,000 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.87 |
Taxes
| Income Tax | 436M |
| Effective Tax Rate | 19.11% |
Stock Price Statistics
The stock price has increased by 38.2% in the
last 52 weeks. The beta is 0.69, so Boston Scientific's
price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | 38.2% |
| 50-Day Moving Average | 99.23 |
| 200-Day Moving Average | 91.64 |
| Relative Strength Index (RSI) | 57.37 |
| Average Volume (20 Days) | 8,544,491 |
Income Statement
In the last 12 months, Boston Scientific had revenue of 16.75B
and earned 1.85B
in profits. Earnings per share was 1.26.
| Revenue | 16.75B |
| Gross Profit | 11.49B |
| Operating Income | 2.6B |
| Net Income | 1.85B |
| EBITDA | 3.94B |
| EBIT | 2.59B |
| Earnings Per Share (EPS) | 1.26 |
Full Income StatementBalance Sheet
The company has 414M in cash and 11.15B in
debt, giving a net cash position of -10.73B.
| Cash & Cash Equivalents | 414M |
| Total Debt | 11.15B |
| Net Cash | -10.73B |
| Retained Earnings | 2.67B |
| Total Assets | 40.14B |
| Working Capital | 2.28B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 3.44B
and capital expenditures -790M, giving a free cash flow of 2.65B.
| Operating Cash Flow | 3.44B |
| Capital Expenditures | -790M |
| Free Cash Flow | 2.65B |
| FCF Per Share | 1.8 |
Full Cash Flow StatementMargins
Gross margin is 68.61%, with operating and profit margins of 15.54% and 11.07%.
| Gross Margin | 68.61% |
| Operating Margin | 15.54% |
| Pretax Margin | 13.63% |
| Profit Margin | 11.07% |
| EBITDA Margin | 23.53% |
| EBIT Margin | 15.54% |
| FCF Margin | 15.79% |
